Research programme: enzyme replacement therapeutics - Aeglea BiotherapeuticsAlternative Names: AEB 2109; AEB 3103; AEB 4104; AECase/AEB3103; AEMase/AEB2109
Latest Information Update: 30 Nov 2016
At a glance
- Originator Aeglea Biotherapeutics
- Class Enzymes
- Mechanism of Action Enzyme replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Homocystinuria; Solid tumours